I'll go with the Fact that Medsafe refused that Placebo Patients should have the treatment as no significant benifit was recognised to the Trial Patients ,,
Living Cell Technologies LimitedACN: 104 028 042ASX: LCTOTCQX: LVCLYASX ANNOUNCEMENTTop-line results of LCT Parkinson’s trial require further analysis10 November 2017 – Sydney, Australia & Auckland, New Zealand – The results of Living CellTechnologies Limited’s Phase IIb clinical study of NTCELL® for Parkinson’s disease have beenunblinded. Three of the four primary endpoints were met. No product or procedure adverse eventsoccurred and there is no evidence of xenogeneic infection in patients and their partners. However, at26 weeks post implant, there is not a statistically significant difference between the groups whoreceived NTCELL and the patients who had sham surgery, as measured by the change in the UnifiedParkinson’s Disease Rating Scale (UPDRS Part III in the off state).NTCELL is a regenerative cell therapy that had shown potential in early trials as a disease-modifyingagent in Parkinson’s disease.The study was designed to confirm the most effective dose of NTCELL, define any placebocomponent of the response and further identify the initial target Parkinson’s disease patient subgroup.The study consisted of three groups of six patients. Two patients from each group had sham surgerywith no NTCELL implanted, to act as a control. Group 1 received 40, group 2 80 and group 3 120microcapsules of NTCELL on each side of the brain.The patients who did not receive NTCELL will receive treatment determined by the Data SafetyMonitoring Board (DSMB). At this stage, the DSMB has recommended that no treatment be given tothe placebo patients.
so the first to be allowed the Treatment are the Placebo Patients... if DSMB allow any more Human Treatments ,,these are at LCT cost,, $$$
